The Technical Analyst
Select Language :
Affimed NV [AFMD]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Affimed NV Price, Forecast, Insider, Ratings, Fundamentals & Signals

Affimed NV is listed at the  Exchange

-0.56% €5.30

America/New_York / 28 mar 2024 @ 16:00


FUNDAMENTALS
MarketCap: 79.15 mill
EPS: -8.56
P/E: -0.620
Earnings Date: Mar 28, 2024
SharesOutstanding: 14.93 mill
Avg Daily Volume: 0.0942 mill
RATING 2024-03-28
B-
Sell
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Buy
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.620 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.11x
Company: PE -0.620 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
€-1.471
(-127.75%) €-6.77
Date: 2024-03-29
Expected Trading Range (DAY)

€ 4.70 - 5.90

( +/- 11.38%)
ATR Model: 14 days

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - €5.30
Forecast 2: 16:00 - €5.30
Forecast 3: 16:00 - €5.30
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price €5.30 (-0.56% )
Volume 0.0807 mill
Avg. Vol. 0.0942 mill
% of Avg. Vol 85.67 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Affimed NV

Last 12 Months

Last 12 months chart data with high, low, open and close for Affimed NV

RSI

Intraday RSI14 chart for Affimed NV

Last 10 Buy & Sell Signals For AFMD

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Affimed NV

AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Last 10 Buy Signals

Date Signal @
RENBTCUSDMar 29 - 05:4169 831
KWENTAUSDMar 29 - 05:40130.29
NULSUSDMar 29 - 05:40$0.856
SCNSOLUSDMar 29 - 05:39217.72
PROUSDMar 29 - 05:38$2.23
RLCUSDMar 29 - 05:40$3.92
MSOLUSDMar 29 - 05:38216.21
API3USDMar 29 - 05:403.79
AUDIOUSDMar 29 - 05:38$0.302
C98USDMar 29 - 05:360.392

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.